⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for breast cancer progression

Every month we try and update this database with for breast cancer progression cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) StudyNCT00553358
Neoplasms, Brea...
Lapatinib
Trastuzumab
Paclitaxel
18 Years - Novartis
CD133 Expression in Mammary Invasive Ductal CarcinomaNCT04873154
Breast Cancer
- Sohag University
Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast CancerNCT00073528
Breast Neoplasm...
Lapatinib
Letrozole
Placebo
18 Years - Novartis
A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.NCT01783444
Breast Cancer
Capecitabine
Exemestane
Everolimus
18 Years - Novartis
A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.NCT01783444
Breast Cancer
Capecitabine
Exemestane
Everolimus
18 Years - Novartis
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase InhibitorNCT03312738
Advanced Breast...
Everolimus
Exemestane
Everolimus Plac...
18 Years - Novartis
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase InhibitorNCT03312738
Advanced Breast...
Everolimus
Exemestane
Everolimus Plac...
18 Years - Novartis
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) StudyNCT00553358
Neoplasms, Brea...
Lapatinib
Trastuzumab
Paclitaxel
18 Years - Novartis
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase InhibitorNCT03312738
Advanced Breast...
Everolimus
Exemestane
Everolimus Plac...
18 Years - Novartis
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: